Publications des scientifiques de l'IRD

Gampini S., Nassouri S., Chippaux Jean-Philippe, Semde R. (2016). Retrospective study on the incidence of envenomation and accessibility to antivenom in Burkina Faso. Journal of Venomous Animals and Toxins Including Tropical Diseases, 22, p. art. 10 [5 p.]. International Conference on Envenomation by Snakebites and Scorpion Stings in Africa, 6., Abidjan (CIV), 2015/06/01-05. ISSN 1678-9199.

Titre du document
Retrospective study on the incidence of envenomation and accessibility to antivenom in Burkina Faso
Année de publication
2016
Type de document
Article référencé dans le Web of Science WOS:000372906800002
Auteurs
Gampini S., Nassouri S., Chippaux Jean-Philippe, Semde R.
Source
Journal of Venomous Animals and Toxins Including Tropical Diseases, 2016, 22, p. art. 10 [5 p.] ISSN 1678-9199
Colloque
International Conference on Envenomation by Snakebites and Scorpion Stings in Africa, 6., Abidjan (CIV), 2015/06/01-05
Background: Snakebite is a common neglected public health issue, especially in poor rural areas of sub-Saharan Africa, Asia and Latin America. Passive immunotherapy with safe and effective antivenom is the only approved treatment for it. This study aimed to determine the incidence of snakebites, and to assess the availability and accessibility of antivenoms, from 2010 to 2014, in Burkina Faso. Methods: The assessment of snakebite cases managed in all health facilities from 2010 to 2014 was performed from the Statistical Yearbook of the Ministry of Health. Antivenom consumption data were collected from the drug wholesalers established in Burkina Faso. Results: Snakebites are among the five leading causes of consultations in health districts. From 2010 to 2014, 114,126 envenomation cases occurred in Burkina Faso, out of which 62,293 (54.6 %) victims have been hospitalized resulting in 1,362 (2 %) deaths. The annual incidence and mortality were respectively 130 bites and 1.75 deaths per 100,000 inhabitants. The amount of antivenom sold by wholesalers were 5,738 vials with a total cost of US 539,055 (annual average = US 107,811). The high cost of these antivenoms (between US 42 and 170 per dose according to brand) limited their use by rural people, the main victims of snakebites, whose income is insufficient. Thus, only 4 % of patients received antivenom treatment over the past five years. The price of antivenom was reduced in 2015 to US 3.4 by a public drug wholesaler. Conclusion: The study confirmed the high burden of snakebites in Burkina Faso. To better manage envenomation, Burkina Faso implemented a strategy consisting in seeking affordable sources of antivenom supply of good quality and innovative mechanisms of subsidy.
Plan de classement
Santé : généralités [050] ; Sciences du monde animal [080]
Description Géographique
BURKINA FASO
Localisation
Fonds IRD [F B010066737]
Identifiant IRD
fdi:010066737
Contact